Abstract:Abstract Recurrence with lethal castration-resistant prostate cancer after androgen deprivation therapy remains the major challenge in treatment of advanced prostate cancer. The main mechanism for the development of castration resistance is continuous androgen receptor signaling via promiscuous or hypersensitive androgen receptor, ligand-independent androgen receptor activation, expression of androgen receptor splice variants lacking the ligand-binding domain but remaining constitutively active, and/or de novo androgen synthesis in the prostate. Several new drugs targeting androgen receptor reactivation, such as abiraterone acetate, are showing benefit in prolonging survival in patients with castration-resistant prostate cancer. However, even this potent inhibitor of androgen synthesis has a relatively short time to disease progression. One potential mechanism is the prevalent upregulation of constitutively active, ligand-binding-domain-truncated androgen receptor splice variants in castration-resistant prostate cancer. Therefore, therapeutic approaches that can diminish the availability of both the full-length and the splice variants of androgen receptor should offer considerable benefit in preventing and inhibiting prostate cancer recurrence after androgen deprivation therapy. In the present study, we show that ginsenoside 20(S)-protopanaxadiol-aglycone (PPD), a steroidal saponin from ginseng, effectively downregulates the abundance and activity of both the full-length and the splice variants of androgen receptor. The effect is manifested by an immediate drop in androgen receptor proteins, followed by a reduction in androgen receptor mRNAs. The initial decrease in androgen receptor proteins could be attributed to PPD induction of proteasome-mediated degradation, possibly as a result of disrupted androgen receptor N-C interaction. Our xenograft studies show that PPD inhibits not only the development of castration-resistant prostate cancer after androgen deprivation but also the growth of prostate tumors that are already castration resistant. The inhibition is accompanied by a pronounced decrease of tumor androgen receptor and serum prostate-specific antigen levels. Our findings therefore provide strong justification and lay the groundwork for an effective treatment modality to improve the therapeutic outcome of androgen deprivation therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3922. doi:1538-7445.AM2012-3922

Synthesis of curcumin derivatives targeting androgen receptor for castration‐resistant prostate cancer therapy

Synthesis of curcumin derivatives for suppression of castration-resistant prostate cancer

Synthesis and Biological Evaluation of 3-Nitro-4-chromanone Derivatives As Potential Antiproliferative Agents for Castration-Resistant Prostate Cancer

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

Synthesis And Biological Evaluation Of Spirocyclic Chromane Derivatives As A Potential Treatment Of Prostate Cancer

ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth Through Degradation of Full-Length and Splice Variant Androgen Receptors.

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants

Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells

Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer.

Identification of Novel Androgen Receptor Degrading Agents to Treat Advanced Prostate Cancer

3D-QSAR and Molecular Docking Studies on Design Anti-Prostate Cancer Curcumin Analogues

Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer

Abstract 3922: 20(S)-Protopanaxadiol-aglycone Inhibition of the Development and Growth of Castration-Resistant Prostate Cancer

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy

The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer

3-O-Carbamoyl-5,7,20-O-trimethylsilybins: Synthesis and Preliminary Antiproliferative Evaluation